Evidence map›Paper›PMID 40081858›Full record

ArticleInternational journal of cancer2025

Real-world treatment patterns and outcomes based on RAS/BRAF status in metastatic colorectal cancer-Analysis of the Prospective Dutch Colorectal Cancer cohort.

Sietske C M W van Nassau, Koen Zwart, Frederieke H van der Baan, Geraldine R Vink, Marloes A G Elferink, Petur Snaebjornsson, Anne M May, Miriam Koopman, Jeanine M L Roodhart

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sietske C M W van NassauDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-6763-6519
Koen ZwartDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0002-0369-4509
Frederieke H van der BaanDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Geraldine R VinkDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Marloes A G ElferinkDepartment of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
Petur SnaebjornssonDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-1086-8108
Anne M MayDepartment of Epidemiology & Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Miriam KoopmanDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Jeanine M L RoodhartDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0003-1398-8970

Funding

Pierre Fabre
6 · The paper itself

Abstract

The treatment landscape for metastatic colorectal cancer (mCRC) has evolved into a continuum of care with an essential role for biomarkers and molecular subgroups. Treatment guidelines are primarily based on trial results; however, populations and outcomes differ from clinical practice. To support the interpretation of trial results and to assist in tailored patient counseling, we evaluated real-world treatment patterns and outcomes according to RAS/BRAF status. We included all patients diagnosed with BRAF

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsProto-Oncogene Proteins B-rafras ProteinsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedMutationNeoplasm MetastasisNetherlandsProgression-Free SurvivalProspective StudiesBRAF protein, humanProto-Oncogene Proteins B-rafras ProteinsBRAFmetastatic colorectal cancerRASreal‐worldtreatment patterns

Identifiers

PMID40081858
PMCPMC12141976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.